Read and Understood. Executive has read this Agreement carefully and understands each of its terms and conditions. Executive has sought independent legal counsel of Executive’s choice to the extent Executive deemed such advice necessary in connection with the review and execution of this Agreement.
Read and Understood. Each party acknowledges that it has read and understands this Agreement and agrees to be bound by its terms.
Read and Understood. Employee has read this Agreement carefully and understands each of its terms and conditions. Employee has sought independent legal counsel of Employee’s choice to the extent Employee deemed such advice necessary in connection with the review and execution of this Agreement.
Read and Understood. Each Party acknowledges that it has read and understands this Agreement and agrees to be bound by its terms and conditions. Engaging the Services of RDR constitutes the Customer’s complete agreement with the terms of this Agreement.
Read and Understood. Each Party acknowledges that it has read and understands this Agreement and agrees to be bound by its terms. If you do not agree to these conditions you should not install this software.
Read and Understood. I (Patient or Patient's representative) have read and I understand the above Agreement which has been verbally explained to me to my satisfaction. I understand that I have the right to have my questions about arbitration answered and I do not have any unanswered questions. I execute this agreement of my own free will and not under any duress, and I understand that my signing this Agreement is not a requirement in order to receive medical services from Physician.
Read and Understood. The parties have read this Agreement carefully and understand each of its terms and conditions. Each party has sought independent legal counsel of choice to the extent the party deemed such advice necessary in connection with the review and execution of this Agreement.
Read and Understood. Xxxxxxxx has read this Agreement carefully and understands each of its terms and conditions. Xxxxxxxx has sought independent legal counsel of his choice to the extent he deemed such advice necessary in connection with the review and execution of this Agreement.
Read and Understood. You acknowledge that you have read and understand this Agreement and agree to be bound by its terms and conditions.
Read and Understood. I confirm that I have received a copy of the Agreement under which this Study Order is issued, and that I have read and understand the Agreement and this Study Order. Date: Name PHILADELPHIA, and HOUSTON, U.S.A. and OXFORD, UK, September XX, 2016 — Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, and The University of Texas MD Xxxxxxxx Cancer Center announced today that they have entered into a multi-year strategic alliance designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer. The alliance pairs MD Anderson’s preclinical and clinical teams with Adaptimmune’s scientists and proprietary SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell technology platform, which enables Adaptimmune to identify targets expressed on solid and hematologic cancers and to develop affinity enhanced T-cell receptors (TCRs) with optimal potency and specificity against them. The teams will collaborate in a number of areas including preclinical and clinical development of Adaptimmune’s SPEAR T-cell therapies targeting MAGE-A10 and future clinical stage first and second generation SPEAR T-cell therapies such as MAGE-A4 across a number of cancers, including bladder, lung, ovarian, head and neck, melanoma, esophageal and gastric cancers. The alliance will also drive research and development of other new SPEAR TCR therapies to targets in other tumor types such as breast cancers and facilitate clinical study participation by MD Xxxxxxxx in other Adaptimmune trials. Access to MD Anderson’s tumor repository will guide further target selection and clinical trial design, while its cancer immunology cores and expertise in performing translational medicine studies may help optimize the efficacy and safety of SPEAR T-cell therapies. “At MD Xxxxxxxx, we are focused on providing the best possible care for cancer patients, including implementing important new technologies and treatment modalities,” said Xxxxxxxxx Xxxxxxxxxx, M.D., Ph.D., associate professor of Breast Surgical Oncology. Xxxxx Xxxx, M.D., associate professor of Investigational Cancer Therapeutics at MD Xxxxxxxx added, “It is our hope this alliance will allow us to address numerous solid tumors and augment the patient’s immune system, directing it against tumors based on their specific molecular makeup.” “We believe that this strategic alliance will provide a strong partnership for the development of multiple new first and subsequent gener...
